Medicenna Therapeutics Corp. (MDNA.TO)
CAD 1.05
(-13.93%)
CAD 1.05
(-13.93%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -16.98 Million CAD | 49.45% |
| 2022 | -33.59 Million CAD | -63.6% |
| 2021 | -20.53 Million CAD | 32.32% |
| 2020 | -30.34 Million CAD | -34.07% |
| 2019 | -22.63 Million CAD | -854.47% |
| 2018 | -2.37 Million CAD | 39.8% |
| 2017 | -3.93 Million CAD | 71.94% |
| 2016 | -14.03 Million CAD | -261.84% |
| 2015 | -3.87 Million CAD | -2989.79% |
| 2014 | -125.56 Thousand CAD | -133.49% |
| 2013 | 374.97 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -35.62 Million CAD | -109.8% |
| 2023 FY | -16.98 Million CAD | 49.45% |
| 2023 Q4 | -16.98 Million CAD | 21.95% |
| 2023 Q3 | -21.75 Million CAD | 15.3% |
| 2023 Q2 | -25.68 Million CAD | 13.26% |
| 2023 Q1 | -29.61 Million CAD | 11.85% |
| 2022 Q3 | -36.15 Million CAD | 9.64% |
| 2022 FY | -33.59 Million CAD | -63.6% |
| 2022 Q1 | -19.3 Million CAD | 6.0% |
| 2022 Q2 | -40 Million CAD | -107.27% |
| 2022 Q4 | -33.59 Million CAD | 7.07% |
| 2021 Q2 | -16.67 Million CAD | 35.59% |
| 2021 Q1 | -25.88 Million CAD | 14.69% |
| 2021 Q4 | -20.53 Million CAD | 12.16% |
| 2021 Q3 | -23.37 Million CAD | -40.23% |
| 2021 FY | -20.53 Million CAD | 32.32% |
| 2020 FY | -30.34 Million CAD | -34.07% |
| 2020 Q4 | -30.34 Million CAD | -30.79% |
| 2020 Q3 | -23.19 Million CAD | 3.89% |
| 2020 Q2 | -24.13 Million CAD | -129.67% |
| 2020 Q1 | -10.5 Million CAD | 53.56% |
| 2019 FY | -22.63 Million CAD | -854.47% |
| 2019 Q3 | -6.97 Million CAD | -252.27% |
| 2019 Q4 | -22.63 Million CAD | -224.5% |
| 2019 Q1 | -1.05 Million CAD | 55.4% |
| 2019 Q2 | -1.97 Million CAD | -87.21% |
| 2018 Q3 | -4.64 Million CAD | -228.49% |
| 2018 Q4 | -2.37 Million CAD | 48.96% |
| 2018 FY | -2.37 Million CAD | 39.8% |
| 2018 Q1 | -1.58 Million CAD | 59.65% |
| 2018 Q2 | -1.41 Million CAD | 11.02% |
| 2017 Q2 | -9.53 Million CAD | 20.75% |
| 2017 Q1 | -12.03 Million CAD | 14.29% |
| 2017 Q3 | -6.39 Million CAD | 32.9% |
| 2017 FY | -3.93 Million CAD | 71.94% |
| 2017 Q4 | -3.93 Million CAD | 38.44% |
| 2016 Q2 | -796.99 Thousand CAD | 0.4% |
| 2016 Q1 | -800.18 Thousand CAD | -226.54% |
| 2016 FY | -14.03 Million CAD | -261.84% |
| 2016 Q4 | -14.03 Million CAD | -170.71% |
| 2016 Q3 | -5.18 Million CAD | -550.65% |
| 2015 Q2 | -865.66 Thousand CAD | -84.5% |
| 2015 Q4 | 632.33 Thousand CAD | 0.0% |
| 2015 Q1 | -469.2 Thousand CAD | 0.0% |
| 2015 FY | -3.87 Million CAD | -2989.79% |
| 2014 FY | -125.56 Thousand CAD | -133.49% |
| 2013 FY | 374.97 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Appili Therapeutics Inc. | 8.09 Million CAD | 309.904% |
| Eupraxia Pharmaceuticals Inc. | -11.72 Million CAD | -44.873% |
| Helix BioPharma Corp. | -1.08 Million CAD | -1470.953% |
| Microbix Biosystems Inc. | -4.96 Million CAD | -242.299% |
| Satellos Bioscience Inc. | -22.06 Million CAD | 23.043% |
| Oncolytics Biotech Inc. | -31.11 Million CAD | 45.415% |
| Sernova Corp. | -8.58 Million CAD | -97.794% |